Note 19 - Subsequent Event	12 Months Ended
Dec. 31, 2013
Subsequent Events [Abstract]
Subsequent Events [Text Block]	19. Subsequent Events On March 3, 2014, the Company submitted its ANDA in 2014 to the FDA, which brings the Company’s total number of ANDA submissions to fourteen. On March 12, 2014, the Company received its first approval from the FDA for an ANDA. The FDA has approved IGI's application for lidocaine hydrochloride USP 4% topical solution. Lidocaine hydrochloride USP 4% topical solution is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract. On March 25, 2014, the Board of Directors of the Company, at the recommendation of its Organization and Compensation Committee, resolved to award a cash bonus in the amount of $75,000 to its President and Chief Executive Officer, Jason Grenfell-Gardner. Mr. Grenfell-Gardner is also a director of the Company. On March 31, 2014, the Company filed a Form 8K disclosing that on March 25, 2014, Joyce Erony, a director and the chairperson of the IGI Laboratories, Inc.’s Board of Directors, advised us that she will not stand for re-election as a director at the Comapny's annual meeting to be held on May 27, 2014. Also included in the 8K, was the announcement that on March 28, 2014, Michael B. Hemric advised the Company that he will be resigning as director of the Company's Board of Directors effective April 1, 2014. We have begun the interview process to appoint new directors to the Company’s Board.

Note 19 - Subsequent Event

12 Months Ended

Dec. 31, 2013

19. Subsequent Events

On March 3, 2014, the Company submitted its ANDA in 2014 to the FDA, which brings the Company’s total number of ANDA submissions to fourteen.

On March 12, 2014, the Company received its first approval from the FDA for an ANDA. The FDA has approved IGI's application for lidocaine hydrochloride USP 4% topical solution. Lidocaine hydrochloride USP 4% topical solution is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract.

On March 25, 2014, the Board of Directors of the Company, at the recommendation of its Organization and Compensation Committee, resolved to award a cash bonus in the amount of $75,000 to its President and Chief Executive Officer, Jason Grenfell-Gardner. Mr. Grenfell-Gardner is also a director of the Company.

On March 31, 2014, the Company filed a Form 8K disclosing that on March 25, 2014, Joyce Erony, a director and the chairperson of the IGI Laboratories, Inc.’s Board of Directors, advised us that she will not stand for re-election as a director at the Comapny's annual meeting to be held on May 27, 2014. Also included in the 8K, was the announcement that on March 28, 2014, Michael B. Hemric advised the Company that he will be resigning as director of the Company's Board of Directors effective April 1, 2014. We have begun the interview process to appoint new directors to the Company’s Board.